View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 29, 2022

EC grants approval for Kite’s cell therapy to treat follicular lymphoma

The latest approval is based on findings from the Phase II ZUMA-5 trial in 122 relapsed or refractory FL patients.

The European Commission (EC) has granted marketing authorisation for Gilead Sciences ’ subsidiary Kite’s CAR T-cell therapy, Yescarta (axicabtagene ciloleucel), to treat adults with relapsed or refractory follicular lymphoma (FL). 

A CD19-directed genetically modified autologous T cell immunotherapy, Yescarta is indicated for FL patients who have received three or more previous lines of systemic therapy. 

The treatment has maintained orphan medicinal product designation for this indication.

The latest approval is based on findings from the global, single-arm Phase II ZUMA-5 clinical trial in 122 relapsed or refractory FL patients. 

These subjects received a minimum of two lines of systemic therapy previously, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. 

At the 24-month assessment, subjects who received three or more lines of previous therapy had an overall response rate (ORR) and complete response (CR) rate of 91% and 77%, respectively.

The median duration of response (DoR) was reported to be 38.6 months while the proportion of responders who were still in response at month 24 was 56%.

Safety observations were in line with Yescarta’s known safety profile. 

In the trial, 6% of the subjects had Grade ≥3 cytokine release syndrome (CRS) while 16% of them had neurologic events. 

Kite CEO Christi Shaw said: “Patients with advanced relapsed or refractory follicular lymphoma have a high need for new treatment options. 

“This is the third approved indication for a Kite cell therapy in Europe, and we are pleased to enable more patients with different lymphomas greater access to this treatment innovation.”

FL is a kind of indolent non-Hodgkin lymphoma (iNHL).

In April this year, the US Food and Drug Administration (FDA) granted approval for Yescarta for adult patients with large B-cell lymphoma.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology